SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Tau Medical is generating significant momentum as investors anticipate the upcoming oral presentation of pancreatic cancer data at Digestive Disease Week, which follows recent FDA and European trial expansion successes. The community is actively discussing a series of near-term clinical milestones and institutional accumulation, viewing the stock as a de-risked opportunity with strong upside potential.

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellia Therapeutics is trending as investors react to the long-awaited FDA clinical hold lift for its gene-editing program and highly positive long-term Phase 3 results, which have triggered intense community discussion around a potential short squeeze given the stock's elevated short interest. While the community is actively debating the significance of the recent shelf offering and its impact on dilution, bullish sentiment remains strong regarding the company's curative technology and upcoming clinical trial milestones.

Domino's Pizza, Inc. engages in the management of a network of company-owned and franchise-owned pizza stores. It operates through the following segments: U.S. Stores, International Franchise, and Supply Chain. The U.S. Stores segment consists primarily of franchise operations. The International Franchise segment comprises a network of franchised stores. The Supply Chain segment manages regional dough manufacturing and food supply chain centers. The company was founded by James Monaghan and Thomas Stephen Monaghan in 1960 and is headquartered in Ann Arbor, MI.

Dominos Pizza Inc

Domino's Pizza is currently drawing significant attention from investors who are closely watching the stock for a potential rebound following a period of range-bound price action and recent earnings volatility. Community sentiment remains polarized, with many market participants viewing the company as a deep-value opportunity and a potential candidate for long-term accumulation, while others express caution regarding competitive pressures and broader consumer spending trends.

RE/MAX Holdings, Inc. engages in the provision of real estate franchise services through its subsidiaries. It operates through the following segments: Real Estate, Mortgage and Marketing Funds. The Real Estate segment consists of the company’s owned and independent global franchising operations under the RE/MAX brand name and technology and data subscription for Gadberry and the First app. The Mortgage segment consists of the firm's mortgage brokerage franchising operations under the Motto Mortgage brand name and mortgage loan processing services and licensed software under the wemlo brand. The Marketing Funds segment is involved in marketing campaigns designed to build and maintain brand awareness and the development and operation of agent marketing technology. The company was founded by David L. Liniger and Gail A. Liniger in 1973 and is headquartered in Denver, CO.

RE/MAX Holdings Inc - Ordinary Shares - Class A

RE/MAX is currently drawing investor attention as it faces ongoing volatility within the broader housing market, with the community actively debating the company's valuation amid cooling home sales data and shifting industry dynamics. While some market participants view the stock as undervalued and point to recent insider buying as a sign of confidence, others remain cautious about potential headwinds from high interest rates and broader economic uncertainty.

QUALCOMM, Inc. engages in developing and commercializing foundational technologies and products used in mobile devices and other wireless products. It operates through the following segments: Qualcomm CDMA Technologies (QCT), Qualcomm Technology Licensing (QTL), and Qualcomm Strategic Initiatives (QSI). The QCT segment develops and supplies integrated circuits and system software based on technologies for use in voice and data communications, networking, application processing, multimedia, and global positioning system products. The QTL segment grants licenses and provides rights to use portions of the firm's intellectual property portfolio. The QSI segment focuses on opening new or expanding opportunities for its technologies and supporting the design and introduction of new products and services for voice and data communications. The company was founded by Franklin P. Antonio, Adelia A. Coffman, Andrew Cohen, Klein Gilhousen, Irwin Mark Jacobs, Andrew J. Viterbi, and Harvey P. White in July 1985 and is headquartered in San Diego, CA.

Qualcomm, Inc.

Qualcomm is facing downward pressure as investors weigh strong record-breaking earnings against softer-than-expected guidance driven by handset memory shortages and broader semiconductor supply chain constraints. Despite these headwinds, the community remains divided, with many long-term bulls highlighting the company's aggressive stock buyback programs, massive automotive backlogs, and strategic pivot toward edge AI and data center opportunities as potential catalysts for a recovery.

Back in 2011, long before “crypto Twitter”, NFTs, or VC-backed chains existed, users of the BitcoinTalk forum came up with a new currency - not to launch a network, but to make fun of btc.... and so: The first memecoin/memecurrency was born.  On May 23, 2011, a Something Awful poster cracked, “Has anyone called them buttcoins yet?”. It was sophomoric and perfect. Within weeks the gag metastasized into Buttcoin.org, a parody blog that described a “peer to peer butt” economy while cataloging mining fiascos, exchange blowups, and MLM-adjacent “innovations”.

Buttcoin

Buttcoin is trending as the community highlights its origin as the first memecurrency dating back to 2011, leveraging its historical lore and satirical roots against Bitcoin to fuel current momentum. Investors are actively discussing the involvement of key figures, locked supply, and the potential for the project to reach significant market valuations based on its long-standing presence in internet culture.

MaxLinear, Inc. engages in the provision of communications systems-on-chip (SoC) solutions used in broadband, mobile and wireline infrastructure, data center, and industrial and multi-market applications. Its products include cable broadband modems and gateways, wireline connectivity devices, radio frequency transceivers, fiber-optic modules, video set-top boxes and gateways, hybrid analog and digital televisions, direct broadcast satellite outdoor and indoor units, and power management and interface products. The company was founded by Kimihiko Imura, Curtis C. Ling, and Kishore V. Seendripu on September 25, 2003 and is headquartered in Carlsbad, CA.

MaxLinear Inc

MaxLinear is currently trending as investors focus on a strong earnings beat and a significant upward revision in revenue guidance, signaling a structural shift toward AI-driven data center infrastructure. The community is actively debating the stock's massive recent price surge, with many market participants comparing the momentum to previous high-volatility winners and speculating on the potential for continued short-squeeze dynamics.

Onyx is an infrastructure for a multi-asset, scalable, and cryptographically secure ledger. Onyx functions as a blockchain-based technology that enhances financial ecosystems by enabling a more efficient and interconnected economy, with a mission to develop cryptographic ledgers that optimize security, scalability, and usability. XCN is native to the Onyx XCN Ledger Blockchain as well as the Onyx Goliath Blockchain. XCN is also used as an ERC-20 token for Staking and Governance.

Onyxcoin

Onyxcoin is seeing heightened community discussion ahead of the anticipated Goliath mainnet launch. While some users are expressing skepticism and frustration over prolonged price consolidation and perceived manipulation, bulls are actively accumulating and highlighting the potential for institutional adoption.

Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of proprietary antibody therapeutics. Its platform includes common light chain-focused antibody discovery, human display for antibody tuning, stitchmabs, and highly modular and manufacturable bispecific candidates. The company was founded by Thomas J. Schuetz in 2014 and is headquartered in Boston, MA.

Compass Therapeutics Inc

Compass Therapeutics is currently drawing significant investor attention due to the upcoming readout of Phase 2/3 topline secondary endpoints for its lead oncology candidate, tovecimig, scheduled for early this week. The community is actively debating the potential for a positive data surprise against historical benchmarks in biliary tract cancer, while closely monitoring for any signs of institutional positioning or volatility ahead of the webcast.

"What's Updog?" is a Community Led token.

UpDog

UpDog is capturing significant community attention as long-term holders and whales accumulate the token, fueled by an active, joke-centric marketing approach. Supporters are highlighting the project's multi-year history and presence on the Jupiter strict list as indicators of a dedicated community preparing for potential growth.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Aktis Oncology (NASDAQ:AKTS) Stock Price Crosses Above Fifty Day Moving Average - Time to Sell?

Aktis Oncology (NASDAQ:AKTS) Stock Crosses Above Fifty Day Moving Average - Time to Sell...

Wall Street Analysts Predict a 74.73% Upside in Aktis (AKTS): Here's  What You Should Know

The mean of analysts' price targets for Aktis (AKTS) points to a 74.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Aktis Oncology (NASDAQ:AKTS) Shares Down 3.7% - Here's Why

Aktis Oncology (NASDAQ:AKTS) Stock Price Down 3.7% - Time to Sell...

Aktis Oncology (NASDAQ:AKTS) Receives Consensus Rating of "Buy" from Analysts

Shares of Aktis Oncology (NASDAQ:AKTS - Get Free Report) have been given an average rating of "Buy" by the five analysts that are presently covering the stock, MarketBeat Ratings reports. Five...

Q1 EPS Estimates for Aktis Oncology Boosted by HC Wainwright

Aktis Oncology (NASDAQ:AKTS - Free Report) - Investment analysts at HC Wainwright increased their Q1 2026 earnings per share (EPS) estimates for Aktis Oncology in a research report issued to clients...

HC Wainwright Comments on Aktis Oncology Q1 Earnings

Aktis Oncology (NASDAQ:AKTS - Free Report) - Research analysts at HC Wainwright issued their Q1 2027 EPS estimates for shares of Aktis Oncology in a research note issued on Tuesday, March 31st. HC...

Aktis Oncology (NASDAQ:AKTS) Given New $33.00 Price Target at HC Wainwright

HC Wainwright boosted their price objective on Aktis Oncology from $30.00 to $33.00 and gave the company a "buy" rating in a report on Tuesday...

Aktis Oncology (NASDAQ:AKTS) Stock Price Up 5.4%  - Time to Buy?

Aktis Oncology (NASDAQ:AKTS) Trading Up 5.4% - Should You Buy...

Aktis Oncology (NASDAQ:AKTS) Sets New 1-Year Low - What's Next?

Aktis Oncology (NASDAQ:AKTS) Reaches New 12-Month Low - What's Next...

Aktis Oncology (NASDAQ:AKTS) Stock Price Passes Below 50-Day Moving Average   - Should You Sell?

Aktis Oncology (NASDAQ:AKTS) Stock Price Crosses Below 50-Day Moving Average - Here's What Happened...

Aktis Oncology, Inc. is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The company was founded by Todd Foley, Patrick Baeuerle and Brian Goodman in August 2020 and is headquartered in Boston, MA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '25	-$0.07	--	--	N/A
Q4 '24	-$0.11	--	--	N/A
Q3 '24	-$0.12	-$0.14	-16.67%	MISSED
Q2 '24	-$0.18	-$0.19	-5.56%	MISSED
Q1 '24	-$0.18	-$0.27	-50.00%	MISSED

AKTS
Akoustis Technologies Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q1 '25

Historical Earnings

Latest AKTS News

AKTSAkoustis Technologies Inc